Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.

By R. Gold, L. Kappos, Douglas L. Arnold, A. Bar-Or, G. Giovannoni, K. Selmaj, C. Tornatore, M. Sweetser, Minhua Yang, S. Sheikh and 1 more. New England Journal of Medicine, 2012

1,653 citations recorded by the source corpus.

Subfields: Developmental Neuroscience, Neurology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/fce384e3ccf711fe8f6f3475e29f96c6047bcc1e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Melba C. Jaramillo
2. Donna D. Zhang
3. Sayantan Datta
4. M. Cano
5. K. Ebrahimi
6. Lei Wang
7. J. Handa
8. Nur Samsu

Citations in the corpus

• Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment (2021, background): “On the other hand, other Nrf2 activators such as dimethyl fumarate are currently used to treat multiple sclerosis [198], as well as research exploring the safety and tolerability of the bardoxolone methyl formulation RTA 402.”
• Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. (2012, neutral): “Any serious adverse event 79 (22) 61 (17) 54 (16) 60 (17)”
• The emerging role of the Nrf2–Keap1 signaling pathway in cancer (2013, background): “In phase III clinical trials for multiple sclerosis (MS), BG-12, an oral preparation of DMF, led to a reduction in the annual relapse rate for MS (Gold et al. 2012).”
• The Impact of Oxidative Stress and Inflammation on RPE Degeneration in Non-neovascular AMD (2017, background): “…with dimethyl fumarate, an Nrf2 activator, in the DEFINE study, which reduced the proportion of patients who had a relapse, the annualized relapse rate, the rate of disability progression, and the number of lesions on MRI for the treatment of relapsing multiple sclerosis (Gold et al., 2012).”